INTRODUCTION {#s1}
============

Tumor cells exhibit an altered metabolism to support their fury proliferation under robust environment. Increased need for glycolysis, known as Warburg effect, and glucose uptake for energy production were identified in various cancers \[[@R1]\]. Although oxidative catabolism was more efficient in ATP production, glycolysis was identified increased along with upregulation of glucose transporters. Recent studies have showed that overexpression of glucose transporters (GLUTs), a protein family responsible for glucose uptake, resulted in enhanced aerobic glycolysis of cancers \[[@R2]\]. To date, 14 members of the glucose transporter family have been reported. Based on the sequence of similarities and structure elements, the glucose transporter family can be divided into three subfamilies \[[@R3]\]. Among them, GLUT1, encoded by the SLC2A1 gene, is likely one of the most extensively studied proteins of all membrane transport systems. GLUT1 is a representative protein of GLUT family and is widely distributed in normal tissues. GLUT1 is primarily undetectable in normal epithelial tissues and benign epithelial tumors. Overexpression of GLUT1 during the oncogenesis has been identified in various cancers, which results in increased glucose uptake into cytoplasm of tumor cells \[[@R4]\].

Given the importance of GLUT1 in oncogenesis, some studies were conducted to investigate the prognostic value of GLUT1 in tumors. However, conflicting results were found across different tumors. Some studies reported that overexpression of GLUT1 was significantly associated with poor survival in patients with different cancers, whereas others found no significant association \[[@R4]\]. Identification of patients with poor prognosis can help develop novel treatment strategies at the beginning of treatment, which may lead to better and more individual therapy strategies with superior survival. Therefore, it is meaningful to further evaluate the prognostic value of GLUT1 in cancers. Here, we conducted a systematic review and meta-analysis of published literature to investigate and determine the prognostic value of GLUT1 among different cancers and to provide objective evidence to support further prospective clinical studies.

RESULTS {#s2}
=======

Study selection and description of the include studies {#s2_1}
------------------------------------------------------

A total of 315 relevant studies were identified after removing duplicated records. The title and abstract of relevant articles were scrutinized by two authors (Yu and Chen) independently, and 247 citations were excluded from the first screening, leaving 68 citations for full-text review. After careful evaluation, only 27 studies with 4079 patients met the inclusion criteria for further analysis (Figure [1](#F1){ref-type="fig"}). The characteristics of the 27 included studies were shown in Table [1](#T1){ref-type="table"}. Briefly, all eligible studies were retrospective studies that contained 49--617 samples and published from 2001 to 2016. All of the included studies measured the expression of GLUT1 by means of immunohistochemistry (IHC) staining or PCR in human tissues, and the cut-off values varied across studies. Among the studies, 4 evaluated lung cancer \[[@R5]--[@R8]\], 3 evaluated pancreatic cancer \[[@R9]--[@R11]\], 3 evaluated breast cancer \[[@R12], [@R14]\], 2 evaluated gallbladder cancer \[[@R10], [@R15]\], 2 evaluated gastric cancer \[[@R16], [@R17]\], 2 evaluated colorectal cancer \[[@R18], [@R19]\], 2 evaluated laryngeal cancer \[[@R20], [@R21]\], and 1 each evaluated hypopharyngeal cancer \[[@R22]\], endometrial cancer \[[@R23]\], salivary gland tumor \[[@R24]\], adrenocortical cancer \[[@R25]\], liver cancer \[[@R26]\], ampulla of Vater cancer \[[@R10]\], extrahepatic bile duct cancer \[[@R10]\], oral cancer \[[@R27]\], neuroblastic tumors \[[@R28]\], cervical cancer \[[@R29]\], ovarian cancer \[[@R30]\] and esophageal cancer \[[@R31]\]. Due to the retrospective design of the included studies, only five studies examined both OS and DFS \[[@R6], [@R12], [@R14], [@R25], [@R29]\]. Sixteen studies investigated the association between GLUT1 level and OS \[[@R7]--[@R11], [@R15]--[@R21], [@R24], [@R27], [@R28], [@R30]\], while four studies investigated the association between GLUT1 and DFS \[[@R5], [@R13], [@R23], [@R26]\]. Studies by Mineta \[[@R22]\] reported relapse-free survival data, whereas study by Sawayama \[[@R31]\] reported data of relapse-free survival and cancer-specific survival. Among the included studies, various antibodies were applied to evaluate the expression of GLUT1. Most of them were produced by Abcam and Dako, with dilution ranging 1:100 to 1:7500. The cut-off values varied dependent on staining score and the detection method. According to Newcastle-Ottawa Scale (NOS) tool, we systematically evaluated the quality of the included studies, and the results were shown in [Supplementary Table 1](#SD1){ref-type="supplementary-material"}. The included studies had a mean score of 7.2 (range 5 to 8), indicating the acceptable quality of included original studies.

![Flow chart of the selection of the studies in the meta-analysis](oncotarget-08-43356-g001){#F1}

###### Characteristics of studies included in the present meta-analysis

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study                        Country       Cancer types                    Patient number   Recruitment time   Age          Follow-up months (median)    Method   Antibody source                 Dilution   Cut-off        Positive rate(%)   Study Quality
  ---------------------------- ------------- ------------------------------- ---------------- ------------------ ------------ ---------------------------- -------- ------------------------------- ---------- -------------- ------------------ ---------------
  Kawamura, 2011 \[[@R16]\]    Japan         Gastric cancer                  617              1987--1989         27--88       NA                           IHC      Polyclonal, Chemicon            1:4000     1.00%          29.5               6

  Furudoi, 2001 \[[@R18]\]     Japan         Colorectal cancer               111              1983--1994         52.5--74.1   49.3--77.1 (mean = 63.2)     IHC      Polyclonal, DAKO                1:100      30%            35.1               7

  Kang, 2002 \[[@R14]\]        Korea         Breast cancer                   100              1996--1997         23--74       49--67\                      IHC      Polyclonal, DAKO                1:200      10%            47                 6
                                                                                                                              (median = 57.4)                                                                                                    

  Mineta, 2002 \[[@R22]\]      Japan         Hypopharyngeal cancer           99               NA                 39--94       6--192\                      IHC      Polyclonal, Chemicon            1:1000     70%            46.5               7
                                                                                                                              (mean = 49)                                                                                                        

  Sebastiani,2004 \[[@R23]\]   Italy         Endometrial cancer              87               1992--1996         27--92       Median = 60                  IHC      Polyclonal, DAKO                NA         score=6        43                 7

  Mori, 2006 \[[@R24]\]        Japan         Salivary gland tumors           49               1990--2005         14--82       NA                           IHC      Polyclonal, DAKO                1:50       15%            26.5               5

  Lyshchik, 2007 \[[@R11]\]    Japan         Pancreatic cancer               74               NA                 40--81       NA                           IHC      Polyclonal, DAKO                1:200      60%            44.6               7

  Legan, 2009 \[[@R15]\]       Slovenia      Gallbladder cancer              50               1998--2005         34--84       NA                           IHC      Polyclonal, DAKO                1:100      50%            58                 5

  Fenske, 2009 \[[@R25]\]      Germany       Adrenocortical cancer           118              NA                 NA           NA                           IHC      Polyclonal, DAKO                1:100      10%            33.8               5

  Kitamura, 2010 \[[@R26]\]    Japan         Liver cancer                    63               2003--2005         32--80       2.5--66.7\                   IHC      Polyclonal, DAKO                1:200      0%             36.5               8
                                                                                                                              (mean = 38)                                                                                                        

  Sung, 2010 \[[@R10]\]        Korea         Gallbladder cancer              115              1983--2007         NA           1--160\                      IHC      Polyclonal, DAKO                1:200      5%             46.1               6
                                                                                                                              (mean = 36)                                                                                                        

  Sung, 2010 \[[@R10]\]        Korea         Pancreatic cancer               52               1983- 2007         NA           2--244\                      IHC      Polyclonal, DAKO                1:200      5%             51.9               6
                                                                                                                              (mean = 28)                                                                                                        

  Sung, 2010 \[[@R10]\]        Korea         Ampulla of Vater cancer         67               1983--2007         NA           1--264\                      IHC      Polyclonal, DAKO                1:200      = 5%           56.7               6
                                                                                                                              (mean = 73)                                                                                                        

  Sung, 2010 \[[@R10]\]        Korea         Extrahepatic bile duct cancer   121              1983- 2007         NA           1--235\                      IHC      Polyclonal, DAKO                1:200      = 5%           31.4               6
                                                                                                                              (mean = 45)                                                                                                        

  Andersen, 2011 \[[@R5]\]     Norway        Lung cancer                     108              1990--2004         28--85       48--216 (median = 86)        IHC      Monoclonal, Abcam               1:500      25%            58.4               8

  Jang, 2012 \[[@R12]\]        Korea         Breast cancer                   276              2000--2009.        Mean= 50     NA\                          IHC      Monoclonal, Abcam               1:250      10%            37.1               6
                                                                                                                              (mean = 60)                                                                                                        

  Sasaki, 2012 \[[@R7]\]       Japan         Lung cancer                     279              2001--2008         29--86       NA                           IHC      Monoclonal, Thermo Scientific   NA         NA             49.1               6

  Kwon, 2013 \[[@R13]\]        Korea         Breast cancer                   207              2000--2010         28--52.4     NA                           IHC      Monoclonal, Abcam               1:200      10%            2.4                5

  Maki, 2013 \[[@R6]\]         Japan         Lung cancer                     105              2004--2006         29--83       NA (median = 59.7)           IHC      Monoclonal, Abcam               1:200      10%            26.7               8

  Grimm, 2013 \[[@R27]\]       USA           Oral cancer                     161              NA                 NA           NA (mean = 52.26)            IHC      Polyclonal, DAKO                1:100      10%            41.6               8

  Ramani, 2013 \[[@R28]\]      UK            Neuroblastic tumors             96               1994--2011         0.001--16    15--195 (median = 86)        IHC      Polyclonal,Merck-Millipore      NA         NA             45.8               8

  Kim, 2013 \[[@R29]\]         Korea         Cervical cancer                 162              1996--2010         NA           6--60 (mean = 55.6)          IHC      Monoclonal, NeoMarkers          1:3000     score = 8      22.8               7

  Cho, 2013 \[[@R30]\]         Korea         Ovarian cancer                  50               2008--2010         NA           NA (mean = 31.6)             IHC      Monoclonal, R&D Systems         NA         score = 3.85   52                 7

  Sawayama, 2014 \[[@R31]\]    Japan         Esophageal cancer               145              2000--2008         NA           1.3--132.3 (median = 39.5)   IHC      Polyclonal, Abcam               1:7500     50%            28.3               8

  Yu, 2015 \[[@R9]\]           China         Pancreatic cancer               106              2000--012          31--77       NA                           IHC      Monoclonal, Epitomics           1:250      score = 2      58.5               8

  Osugi, 2015 \[[@R8]\]        Japan         Lung cancer                     134              1998--2000         48--87       NA                           IHC      Polyclonal, DAKO                1:500      50%            56                 5

  Starska, 2015 \[[@R20]\]     Poland        Laryngeal cancer                106              2003--2011         62.4 ± 9.1   NA                           PCR      NA                              NA         NA             83.9               6

  Hans, 2015 \[[@R17]\]        Germany       Gastric cancer                  150              2006--2011         NA           NA (mean = 33.2)             IHC      NA                              1:100      = 10%          22                 7

  Goos, 2015 \[[@R19]\]        Netherlands   Colorectal cancer               214              1990--2010         NA           NA                           IHC      Polyclonal, Abcam               1:600      NA             50                 8

  Zuo, 2016 \[[@R21]\]         China         Laryngeal cancer                57               2012--2014         NA           NA                           IHC      NA, Epitomics                   NA         NA             NA                 5
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Abbreviations: NA, not available; IHC, immunohistochemistery; WB, western blotting; TMA, tissue microarrayers.

Prognostic value of GLUT1 {#s2_2}
-------------------------

A total of 232 patients in three studies \[[@R9]--[@R11]\] were included for evaluating the prognostic value of GLUT1 in pancreatic cancer. Results suggested that high expression of GLUT1 was associated with shorter overall survival in pancreatic cancer (fixed-effect model; HR = 1.469, 95% CI = 1.134--1.903, *p* = 0.004; *I*^2^ = 0%, *p* = 0.624). As for lung cancer \[[@R6]--[@R8]\] in three studies involved 518 patients, the pooled results suggested overexpression of GLUT1 had a significantly poor survival effect on OS (fixed-effect model; HR=2.188, 95% CI=1.348--3.553, *p* = 0.002; *I*^2^ = 0%, *p* = 0.685).

Since only a small part of studies reported other cancers, we just presented the qualitative summary and gave up quantitative synthesis. Some studies indicated that there was a poor prognostic value of GLUT1 in oral squamous cell carcinoma \[[@R27]\], malignant salivary gland tumors \[[@R24]\], colorectal cancer \[[@R18], [@R19]\], gastric cancer \[[@R16], [@R17]\], gallbladder cancer \[[@R10], [@R15]\], extrahepatic bile duct cancer \[[@R10]\], adrenocortical carcinoma \[[@R25]\] and neuroblastic tumor \[[@R28]\]. Others studies found there was no significant association between GLUT1 expression with prognosis in laryngeal cancer \[[@R20], [@R21]\], ampulla of vater cancer \[[@R10]\], extrahepatic bile duct cancer \[[@R10]\], cervical cancer \[[@R29]\], and ovarian cancer \[[@R2]\]. As for breast cancer, Kang \[[@R14]\] found there was no significant association between GLUT1 expression with OS, while Jang \[[@R12]\] identified a poor prognostic value of GLUT1 in their studies.

Among the studies reporting the OS data, the pooled results indicated that overexpression of GLUT1 was significantly associated with unfavorable OS (HR = 1.780, 95% CI = 1.574--2.013, *p \<* 0.001). No significant heterogeneity was observed and the fixed-effect model was applied (I^2^ = 0.00%, *p* = 0.542) (Figure [2A](#F2){ref-type="fig"}).

![Forest plot of hazard ratio (HR) for the association between GLUT1 expression and OS (**A**) and DFS(**B**)](oncotarget-08-43356-g002){#F2}

There were nine studies reporting the DFS data \[[@R5], [@R6], [@R12]--[@R14], [@R23], [@R25], [@R26], [@R29]\]. Results showed that overexpression of GLUT1 was significantly associated with unfavorable DFS (HR=1.950, 95% CI =1.229--3.095, *p* = 0.003). There was statistically significant heterogeneity across the studies and the random-effect model was applied (I^2^ = 66.2%, *p* = 0.005) (Figure [2B](#F2){ref-type="fig"}).

Only two studies reported the RFS data, and qualitative summary was present. Study from Sawayama \[[@R31]\] found that overexpression of GLUT1 was associated with poor RFS in esophageal squamous cell carcinoma, whereas Mineta \[[@R22]\] found no significant association between GLUT1 and RFS in hypopharyngeal cancer. Besides, study from Sawayama \[[@R31]\] also indicated that overexpression of GLUT1 showed a significant disadvantage for esophageal cancer-specific survival.

Correlation of GLUT1 expression with clinicopathological features {#s2_3}
-----------------------------------------------------------------

As shown in Figure [3](#F3){ref-type="fig"}, overexpression of GLUT1 was identified to be significantly associated with poor differentiated tumors (RR = 1.380, 95% CI = 1.086 -- 1.755, *p* = 0.009; I^2^ = 72.0%, *p* \< 0.001) (Figure [3A](#F3){ref-type="fig"}), positive lymph node metastasis (RR = 1.395, 95% CI = 1.082--1.799, *p* = 0.010; I^2^ = 70.8%, *p* = 0.002) (Figure [3B](#F3){ref-type="fig"}) and larger tumor size (RR = 1.405, 95% CI = 1.231 -- 1.603, *p \<* 0.001; I^2^ = 37.3%, *p* = 0.093) (Figure [3C](#F3){ref-type="fig"}). The overexpression of GLUT1 did not appear to be associated with age (RR = 1.063, 95% CI = 0.959--1.178, *p* = 0.244; I^2^ = 0.0%, *p* = 0.637) ([Supplementary Figure 1A](#SD1){ref-type="supplementary-material"}) and gender (RR = 1.196, 95% CI = 0.977--1.464, *p* = 0.083; I^2^ = 60.5%, *p* = 0.002) ([Supplementary Figure 1B](#SD1){ref-type="supplementary-material"}). In addition, overexpression of GLUT1 was more likely to be found in tumors with abnormal expression of p53. However, no significant relationship was identified in the pooled results (RR = 1.174, 95% CI = 0.953--1.448, *p* = 0.132; I^2^ = 32.8%, *p* = 0.190) (Figure [3D](#F3){ref-type="fig"} ).

![Forest plot of hazard ratio (HR) for the association between GLUT1 expression and characteristics parameters: poor differentiated tumors (**A**), positive lymph node metastasis (**B**), larger tumor size (**C**) and abnormal expression of p53 (**D**).](oncotarget-08-43356-g003){#F3}

Heterogeneity {#s2_4}
-------------

To explore the potential source of heterogeneity found in these analysis, subgroup analysis and sensitivity analysis were performed. Exploratory subgroup analyses were conducted according to ethnicity, sample size, cancer types, recruitment time, antibody source, methods of positive GLUT1 evaluation, study quality and cut-off value in OS. As indicated in Table [2](#T2){ref-type="table"}, these variables did not alter the prognostic value of GLUT1 in OS. Interestingly, the prognostic impact of GLUT1 was numerically higher in the group of studies with larger sample size (\> 100) (HR= 1.828, 95% CI = 1.583--2.111, *p \<* 0.001), group of studies on non-gastrointestinal cancer (HR=2.132, 95% CI = 1.607--2.828, *p \<* 0.001), group of studies using Dako antibody (HR = 1.927, 95% CI = 1.573--2.360, *p \<* 0.001), group of studies using high cut-off value (range = 10%--100%) (HR = 2.325, 95% CI = 1.365-3.960, *p* = 0.002).

###### Subgroup analyses for overall survival (OS) and disease-free survival (DFS)

  Outcome                                                                                       Characteristics      Number of studies   I-square   Hazard Ratio (95% confidence interval)   Lower CI   Upper CI   *P* value
  --------------------------------------------- ----------------------------------------------- -------------------- ------------------- ---------- ---------------------------------------- ---------- ---------- -----------
  OS                                            **Ethnicity**                                   **Between groups**                                                                                                 
                                                Caucasian                                       7                    0.00%               1.859      1.492                                    2.318      \< 0.001   
                                                Asian                                           14                   7.20%               1.771      1.51                                     2.078      \< 0.001   
  **Sample size**                               **Between groups**\*                                                                                                                                               
                                                \< 100                                          8                    0.00%               1.658      1.31                                     2.098      \< 0.001   
                                                \> 100                                          14                   0.00%               1.828      1.583                                    2.111      \< 0.001   
  **Cancer types**                              **Between groups**                                                                                                                                                 
                                                Gastrointestinal cancer                         11                   17.80%              1.738      1.488                                    2.031      \< 0.001   
                                                other cancers                                   10                   0.00%               2.132      1.607                                    2.828      \< 0.001   
  **Recruitment time (Starting time)**          **Between groups**                                                                                                                                                 
                                                Before 2000                                     10                   21.20%              1.865      1.538                                    2.262      \< 0.001   
                                                After 2000                                      8                    0.00%               1.922      1.461                                    2.53       \< 0.001   
                                                Others                                          3                    20.20%              1.628      1.194                                    2.22       0.002      
  **Antibody source**                           **Between groups**                                                                                                                                                 
                                                Dako                                            9                    24.80%              1.927      1.573                                    2.36       \< 0.001   
                                                Abcam                                           3                    0.00%               1.715      1.18                                     2.492      0.005      
                                                others                                          9                    0.00%               1.657      1.351                                    2.033      \< 0.001   
  **Evaluation of positive GLUT1 expression**   **Between groups**                                                                                                                                                 
                                                Percentage of positive cells                    12                   21.80%              1.819      1.528                                    2.166      \< 0.001   
                                                Combination of intensity and percentage score   3                    0.00%               1.716      1.099                                    2.821      0.019      
                                                Others                                          6                    0.00%               1.863      1.426                                    2.433      \< 0.001   
  **Study quality**                             **Between groups**                                                                                                                                                 
                                                ≥ 7                                             10                   6.20%               1.775      1.574                                    2.013      \< 0.001   
                                                \< 7                                            11                   0.00%               1.796      1.533                                    2.105      \< 0.001   
  **Cut-off value**                             **Between groups**                                                                                                                                                 
                                                Low level (range = 0%--10%)                     8                    0.00%               1.72       1.46                                     2.027      \< 0.001   
                                                High level (range = 10%--100%)                  5                    65.80%              2.325      1.365                                    3.96       0.002      
                                                Others                                          8                    0.00%               1.78       1.574                                    2.013      \< 0.001   
  DFS                                           **Ethnicity**                                   **Between groups**                                                                                                 
                                                Asian                                           6                    10.30%              1.871      1.186                                    2.951      0.007      
                                                Caucasian                                       3                    86.40%              2.026      0.856                                    4.794      0.108      
  **Sample size**                               **Between groups**                                                                                                                                                 
                                                \< 100                                          3                    56.30%              1.657      0.702                                    3.913      0.249      
                                                \> 100                                          6                    46.70%              2.141      1.286                                    3.565      0.003      
  **Cancer types**                              **Between groups**                                                                                                                                                 
                                                Gastrointestinal cancer                         1                    NA                  3.32       0.908                                    12.139     0.07       
                                                other cancers                                   8                    67.70%              1.86       1.151                                    3.005      0.011      
  **Recruitment time**                          **Between groups**                                                                                                                                                 
                                                Start before 2000                               4                    51.90%              1.298      0.837                                    2.013      0.243      
                                                Start after 2000                                4                    0.00%               2.326      1.401                                    3.861      0.001      
                                                Others                                          1                    NA                  6.01       2.146                                    16.831     0.001      
  **Detection methods**                         **Between groups**                                                                                                                                                 
                                                IHC only                                                                                                                                                           
                                                IHC +TMA, IHC+WB                                                                                                                                                   
  **Antibody source**                           **Between groups**                                                                                                                                                 
                                                Dako                                            4                    79.80%              2.494      0.882                                    7.051      0.085      
                                                Abcam                                           4                    0.00%               2.091      1.41                                     3.101      0          
                                                others                                          1                    NA                  0.96       0.438                                    2.102      0.919      
  **Evaluation of positive GLUT1 expression**   **Between groups**                                                                                                                                                 
                                                Percentage of positive cells                    7                    0.00%               2.463      1.745                                    3.477      0          
                                                Combination of intensity and percentage score   2                    0.00%               1.006      0.806                                    1.256      0.958      
  **Study quality**                             **Between groups**                                                                                                                                                 
                                                ≥ 7                                             5                    63.10%              1.544      0.916                                    2.602      0.103      
                                                \< 7                                            4                    17.90%              2.685      1.5                                      4.805      0.001      
  **Cut-off value**                             **Between groups**                                                                                                                                                 
                                                Low level (range = 0%--10%)                     6                    0.00%               2.788      1.804                                    4.309      0          
                                                High level (range = 10%--100%)                  1                    NA                  2          1.138                                    3.516      0.016      
                                                Others                                          2                    0.00%               1.006      0.806                                    1.256      0.958      

Subgroup analyses were also carried out to explore source of heterogeneity in DFS. As shown in Table [2](#T2){ref-type="table"}, the prognostic value of GLUT1 in DFS was worse with respect to Asian group (HR = 1.871, 95% CI = 1.186--2.951, *p* = 0.007), larger sample size (HR = 2.141, 95% CI = 1.286--3.565, *p* = 0.007), late recruitment time (HR = 2.326, 95% CI = 1.401--3.861, *p* = 0.001), antibody produced by Abcam (HR = 2.091, 95% CI = 1.410--3.101, *p* \< 0.001) and low study quality (HR = 2.685, 95% CI = 1.500--4.805, *p* = 0.001). The prognostic value of GLUT1 in DFS was also altered based on cancer types, methods of positive GLUT1 evaluation and cut-off values. However, these results needed to be interpreted cautiously because of the small number of eligible studies.

To gauge the stability of the results, sensitivity analysis was performed by assessing the potential impact of individual study on pooled data. As shown Table [3](#T3){ref-type="table"}, the pooled results of OS and DFS was not significantly altered after exclusion of any study, indicating the robustness of present results ([Supplementary Figure 2A and 2B](#SD1){ref-type="supplementary-material"}).

###### The influence of individual study on the pooled estimate for outcomes

  Outcome                       Study omitted               Estimate   \[95% confidence interval\]   
  ----------------------------- --------------------------- ---------- ----------------------------- -------
  OS                            Kawamura, 2011 \[[@R19]\]   1.862      1.628                         2.129
  Furudoi, 2001 \[[@R21]\]      1.731                       1.527      1.961                         
  Kang, 2002 \[[@R17]\]         1.786                       1.579      2.020                         
  Mori, 2006 \[[@R27]\]         1.765                       1.560      1.997                         
  Lyshchik, 2007 \[[@R14]\]     1.845                       1.621      2.100                         
  Legan, 2009 \[[@R18]\]        1.746                       1.540      1.979                         
  Fenske, 2009 \[[@R28]\]       1.778                       1.567      2.018                         
  Sung, 2010 \[[@R13]\]         1.744                       1.535      1.981                         
  Sung, 2010 \[[@R13]\]         1.802                       1.587      2.046                         
  Sung, 2010 \[[@R13]\]         1.786                       1.578      2.022                         
  Sung, 2010 \[[@R13]\]         1.783                       1.571      2.024                         
  Jang, 2012 \[[@R15]\]         1.763                       1.557      1.996                         
  Sasaki, 2012 \[[@R10]\]       1.751                       1.544      1.986                         
  Maki, 2013 \[[@R9]\]          1.780                       1.574      2.013                         
  Grimm, 2013 \[[@R30]\]        1.763                       1.555      1.999                         
  Ramani, 2013 \[[@R31]\]       1.770                       1.563      2.003                         
  Kim, 2013 \[[@R32]\]          1.780                       1.574      2.013                         
  Cho, 2013 \[[@R33]\]          1.782                       1.575      2.015                         
  Yu, 2015 \[[@R12]\]           1.780                       1.569      2.020                         
  Osugi, 2015 \[[@R11]\]        1.785                       1.577      2.020                         
  Starska, 2015 \[[@R23]\]      1.792                       1.583      2.028                         
  Goos, 2015 \[[@R22]\]         1.807                       1.589      2.054                         
  Hans, 2015 \[[@R20]\]         1.783                       1.572      2.022                         
  Zuo, 2016 \[[@R24]\]          1.783                       1.576      2.016                         
  Combined                      1.780                       1.574      2.013                         
  DFS                           Kang, 2002 \[[@R17]\]       1.916      1.179                         3.114
  Sebastiani, 2004 \[[@R26]\]   2.218                       1.466      3.354                         
  Fenske, 2009 \[[@R28]\]       1.633                       1.087      2.453                         
  Kitamura, 2010 \[[@R29]\]     1.860                       1.151      3.005                         
  Andersen, 2011 \[[@R8]\]      1.986                       1.156      3.413                         
  Jang, 2012 \[[@R15]\]         1.968                       1.155      3.353                         
  Kwon, 2013 \[[@R16]\]         2.008                       1.235      3.264                         
  Maki, 2013 \[[@R9]\]          1.828                       1.153      2.897                         
  Kim, 2013 \[[@R32]\]          2.214                       1.308      3.747                         
  Combined                      1.950                       1.229      3.095                         

Publication bias {#s2_5}
----------------

We assessed the publication bias by visually assessing a funnel plot for asymmetry and by quantitatively performing Begg\'s test and Egger\'s test. The funnel plots showed evidence for symmetry in both OS (Figure [4A](#F4){ref-type="fig"}) and DFS (Figure [4B](#F4){ref-type="fig"}). No publication bias was found in the overall survival meta-analysis (Begg\'s test, *p* = 0.359; Egger\'s test, *p* = 0.207). The Egger\'s test was significant (*p* = 0.022) for publication bias but not the Begg\'s test (*p* = 0.917) in the disease-free survival meta-analysis. Considering the non-normal distribution of the included patient numbers and the discrepancies of these two tests, the Egger test is not to be trusted. Therefore, there is no significant publication bias in the above analyses (Figure [4](#F4){ref-type="fig"}). The finding was another strong evidence to verify that GLUT1 was an independent prognostic factor in various tumors.

![Funnel plot for the assessment of publication bias in this study\
(**A**) Funnel plot for 21 studies reporting overall survival. (**B**) Funnel plot for 9 studies reporting disease-free survival.](oncotarget-08-43356-g004){#F4}

DISCUSSION {#s3}
==========

Overexpression of GLUT1 may represent a key mechanism by which malignant cells may achieve increased glucose uptake and compensate the lack of energy caused by inefficient anaerobic glycolysis \[[@R2]\]. Therefore, the prognostic value of GLUT1 have been extensively explored in various cancers \[[@R5]--[@R31]\]. However, inconsistent results were found in different studies \[[@R12], [@R14], [@R29]\]. So far, there is no meta-analysis regarding the association between GLUT1 expression and survival of tumors. To provide comprehensive and reliable conclusions, we conducted the present meta-analysis to assess the prognostic value of GLUT1 in tumors. Our comprehensive meta-analysis of 4079 patients included in 27 different studies indicated that overexpression of GLUT1 associated with worse OS and DFS. Moreover, we provided evidence that abnormal expression of GLUT1 was significantly associated with poor differentiated tumors, positive lymph node metastasis and larger tumor size, which suggested that overexpression of GLUT1 linked with enhanced invasive potential, proliferative activity, and decreased patient survival. Subgroup analyses were performed to explore the source of heterogeneity based on ethnicity, sample size, cancer types, recruitment time, antibody source, methods of positive GLUT1 evaluation, study quality and cut-off value. We found that these variables did not alter the prognostic value of GLUT1 in OS, whereas prognostic value of GLUT1 in DFS was more obvious in Asian group, larger sample size, late recruitment time, antibody produced by Abcam and low study quality. In light of these findings, we hypothesized that GLUT1 may contribute to the pathogenesis of cancers. Therefore, GLUT1 may be an ideal prognostic factor in various cancers.

However, the mechanism how GLUT1 contributes to the oncogenesis remains unclear. Previous studies have pointed out that significantly higher GLUT1 mRNA expression levels were identified in various cancer tissues and cell lines compared to normal cells and matched non-tumor tissue. Further suppression of GLUT1 expression significantly impaired both the survival and migratory potential of cancer cells. Moreover, inhibition of GLUT1 chemosensitized head and neck cancer cells to cisplatin \[[@R32]--[@R35]\]. Recent studies found that GLUT1 overexpression significantly upregulated the expression of NFκB-p65, and it was reversed by inhibition of GLUT1 expression \[[@R33]\]. Given the oncogenic role of NFκB-p65 in tumorigenicity, the survival effects of GLUT1 may be associated with the activation of the NFκB pathway \[[@R36]\]. Recent study identified that translocation of GLUT1 onto the plasma membrane from para-glogian area was dependent on activation of the PI3KC1-AKT pathway. The results suggested that overexpression of GLUT1 in proliferating cancer cells was associated with the abnormal activation of the PI3KC1-AKT pathway, consequent to the mutational activation of PI3KC1 and/or the loss of PTEN \[[@R37]\]. In addition, several signaling molecules and pathways were showed to be involved in the regulation of expression and distribution of GLUT1, such as hypoxia induced factor 1, c-Myc, Ras and p53 signaling pathway \[[@R38]\], which suggested that signaling network was really complex in regulation of GLUT1. Further elucidation of signaling network of GLUT1 may provide novel methods for detection and treatment of cancer. Currently, GLUT1 expression could be measured simply and inexpensively as part of the routine histologic biopsy of tumors samples prior to operation \[[@R9]\]. The present results may vary from other meta analyses with respect to colorectal cancer, breast cancer and oral squamous cell carcinoma, which is partly attributed to different inclusion criteria and different research Interests \[[@R39]--[@R43]\]. Unlike other meta-analyses, our present analysis not only assess the association between GLUT1 and nineteen kinds of cancers, but also employed HR to assess the impact of GLUT1 on survival. The number of eligible studies is small because of the strict inclusion criteria. However, the quality of the included study and the reliability of present results were guaranteed. Evidence showed that it is not suitable to use OR or RR in a meta-analysis of time-to-event outcomes. Those dichotomous measures can result in combining trials reported at different stages of maturity, with variable follow up, resulting in an estimate that is both unreliable and difficult to interpret \[[@R44]\]. Therefore, we applied HR to estimate the prognostic value of GLUT1 in various cancers. According to the results in present analysis, GLUT1 has an ideal prognostic value in various cancers, and the feasible histologic biopsy may be helpful for more adequate clinical decision.

Certainly, further studies are essential to confirm the credibility of our result. Some important limitations of this meta-analysis should be considered when interpreting the results. Firstly, only papers published in English was included, which probably introduced bias. Secondly, different methods of survival data analysis in different studies should be considered as a potential source of heterogeneity. Although most studies adjusted their HRs and 95% CIs using multivariate analysis, variables added into Cox proportional hazard models were different from study to study. Thirdly, GLUT1 staining was heterogeneous, cytoplasmic and membranous. Most of the included studies did not evaluate the cytoplasmic and membranous staining separately. Therefore, the individual prognostic value of cytoplasmic and membranous GLUT1 remains further evaluation. Finally, metabolism is a complex, multistep, and highly dynamic process. Therefore, a prognostic model integrating a group of valuable metabolic markers may be more accurate in predicting cancer prognosis.

CONCLUSIONS {#s4}
===========

To sum up, this systematic review and meta-analysis indicated that a low expression of the GLUT1 predicted favorable prognosis in gallbladder cancer, pancreatic cancer, breast cancer, and lung cancer. However, due to the limitations in terms of quality and quantity of published original articles, the clinical utility of this biomarker is still reliant on future validation. Therefore, more high-quality, large-sample, prospectively designed studies are highly recommended.

MATERIALS AND METHODS {#s5}
=====================

Publication search strategy and selection criteria {#s5_1}
--------------------------------------------------

Up to May 2016, a systematic search was conducted using PubMed, Medline, Springer and Cochrane library. We identified articles using the following search strategies: (cancer OR carcinoma OR neoplasm OR tumor) AND (prognos\* OR surviv\*) AND (GLUT1 OR Glucose transporter-1 OR SLC2A1). Studies included in our study had to meet the following criteria: (1) hazard ratio (HR) and 95% confidence interval (CI) for overall survival (OS)/disease-free survival (DFS)/relapse-free survival(RFS)were reported or could be extracted from data presented; (2) when the same group of patients was reported in multiple studies, the most informative one was included; (3) availability of full papers in English; (4) assessment of the expression of GLUT1 in human tissues and the sample size of the study was more than 40 patients. The exclusion criteria were as follows: (1) literature reviews, comments, letters, or duplicated publications; (2) no sufficient data to estimate the HR and 95% CI; or (3) the full text could not be retrieved even if the contact with authors had been made.

Data extraction and quality assessment {#s5_2}
--------------------------------------

Two authors (Yu and Chen) carefully read the full texts independently and extracted the data to avoid bias in the process of data-abstraction. The following information was recorded: the first author\'s name, the country of authors, the year of publication, cancer types, patient number, age, follow-up months, detection method, primary antibody, dilution concentration, cut-off value, positive rate and so on. The Newcastle-Ottawa Scale was applied to assess the quality of each included study. The NOS criteria was scored based on three aspects: (1) subject selection, (2) comparability of subject, (3) clinical outcome. Scores based on NOS of 1--3, 4--6, and 7--9 were defined as low-, intermediate-, and high-quality studies, respectively. All disagreements were discussed and resolved with consensus.

Statistical analysis {#s5_3}
--------------------

Meta-analysis was performed using the Stata (version 11 for Windows). For the quantitative aggregation of the survival results, HRs and their 95% CIs were used. In some studies, where HRs and corresponding 95% CIs of low expression versus high expression were provided, we calculated reciprocal to get high expression versus low expression data. In studies where HRs and corresponding 95% CIs were not directly reported, we estimated these values on the basis of available data, such as survival curves, using the methods developed by Parmar \[[@R45]\], Williamson \[[@R46]\], and Tierney \[[@R44]\]. When analyzing the relationship between GLUT1 and clinicopathological factors, risk ratios (RR) and their 95% CI were applied. Heterogeneity was assessed by the Chi-squared test and *p value* in our meta-analysis. I^2^ value was used to evaluate the heterogeneity, fixed-effect model was used if there was I^2^ = 0--50%, which means no significant heterogeneity. Otherwise, the random-effects model was applied. Forest plots were used to illustrate the HRs and 95% CIs of each included study and the results were pooled. To visually assess the possibility of publication bias in a meta-analysis, we produced a funnel plot of the estimated effects. Further Egger\'s test and Begg\'s test were performed to weigh the potential publication bias. Sensitivity analysis was performed by extraction of each single study to investigate the stability of the results. All *p* values were two-side, being statistically significant when *p value* less than 0.05. As for only two studies were focused on RFS data, we just presented the qualitative summary and gave up quantitative synthesis.
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